309 related articles for article (PubMed ID: 6487446)
1. A protocol for the investigation of malignant hyperpyrexia (MH) susceptibility. The European Malignant Hyperpyrexia Group.
Br J Anaesth; 1984 Nov; 56(11):1267-9. PubMed ID: 6487446
[TBL] [Abstract][Full Text] [Related]
2. Malignant hyperthermia (MH) diagnostics: a comparison between the halothane-caffeine- and the ryanodine-contracture-test results in MH susceptible, normal and control muscle.
Hartung E; Koob M; Anetseder M; Schoemig P; Krauspe R; Hogrefe G; Engelhardt W
Acta Anaesthesiol Scand; 1996 Apr; 40(4):437-44. PubMed ID: 8738688
[TBL] [Abstract][Full Text] [Related]
3. Classification of malignant hyperthermia-equivocal patients by 4-chloro-M-cresol.
Gilly H; Musat I; Fricker R; Bittner RE; Steinbereithner K; Kress HG
Anesth Analg; 1997 Jul; 85(1):149-54. PubMed ID: 9212139
[TBL] [Abstract][Full Text] [Related]
4. Sources of variability in halothane and caffeine contracture tests for susceptibility to malignant hyperthermia.
Ording H; Bendixen D
Eur J Anaesthesiol; 1992 Sep; 9(5):367-76. PubMed ID: 1396623
[TBL] [Abstract][Full Text] [Related]
5. An analysis of the predictive probability of the in vitro contracture test for determining susceptibility to malignant hyperthermia.
Hopkins PM; Ellis FR; Halsall PJ; Stewart AD
Anesth Analg; 1997 Mar; 84(3):648-56. PubMed ID: 9052318
[TBL] [Abstract][Full Text] [Related]
6. In vitro contracture test for diagnosis of malignant hyperthermia following the protocol of the European MH Group: results of testing patients surviving fulminant MH and unrelated low-risk subjects. The European Malignant Hyperthermia Group.
Ording H; Brancadoro V; Cozzolino S; Ellis FR; Glauber V; Gonano EF; Halsall PJ; Hartung E; Heffron JJ; Heytens L; Kozak-Ribbens G; Kress H; Krivosic-Horber R; Lehmann-Horn F; Mortier W; Nivoche Y; Ranklev-Twetman E; Sigurdsson S; Snoeck M; Stieglitz P; Tegazzin V; Urwyler A; Wappler F
Acta Anaesthesiol Scand; 1997 Sep; 41(8):955-66. PubMed ID: 9311391
[TBL] [Abstract][Full Text] [Related]
7. [Diagnosis of susceptibility to malignant hyperthermia using the in vitro contracture test].
Klein W; Spiess-Kiefer C; Küther G; Pongratz D; Lehmann-Horn F
Anaesthesist; 1987 Dec; 36(12):685-91. PubMed ID: 2830805
[TBL] [Abstract][Full Text] [Related]
8. [Diagnosis of malignant hyperthermia susceptibility. 1. The significance of in vitro susceptibility tests].
Mortier W; Breucking E
Anaesthesist; 1993 Oct; 42(10):675-83. PubMed ID: 8250201
[TBL] [Abstract][Full Text] [Related]
9. Results of in vitro contracture testing of both parents of malignant hyperthermia susceptible probands.
Islander G; Bendixen D; Ranklev-Twetman E; Ording H
Acta Anaesthesiol Scand; 1996 May; 40(5):579-84. PubMed ID: 8792888
[TBL] [Abstract][Full Text] [Related]
10. Is the "K-type" caffeine-halothane responder susceptible to malignant hyperthermia?
Ellis FR; Halsall PJ; Hopkins PM
Br J Anaesth; 1992 Nov; 69(5):468-70. PubMed ID: 1467078
[TBL] [Abstract][Full Text] [Related]
11. Clinical concentrations of verapamil affect the in vitro diagnosis of susceptibility to malignant hyperpyrexia.
Adnet PJ; Krivosic-Horber RM; Adamantidis MM; Haudecoeur G; Reyfort GH; Dupuis BA
Br J Anaesth; 1990 Jan; 64(1):64-6. PubMed ID: 2302378
[TBL] [Abstract][Full Text] [Related]
12. In vitro diagnosis of susceptibility to malignant hyperthermia: evaluation of tests with halothane-caffeine, potassium chloride, suxamethonium and caffeine-suxamethonium.
Ording H; Skovgaard LT
Acta Anaesthesiol Scand; 1987 Jul; 31(5):462-5. PubMed ID: 3630591
[TBL] [Abstract][Full Text] [Related]
13. Investigation of malignant hyperthermia in Denmark and Sweden.
Ording H; Ranklev E; Fletcher R
Br J Anaesth; 1984 Nov; 56(11):1183-90. PubMed ID: 6487440
[TBL] [Abstract][Full Text] [Related]
14. 4-Chloro-m-cresol test--a possible supplementary test for diagnosis of malignant hyperthermia susceptibility.
Ording H; Glahn K; Gardi T; Fagerlund T; Bendixen D
Acta Anaesthesiol Scand; 1997 Sep; 41(8):967-72. PubMed ID: 9311392
[TBL] [Abstract][Full Text] [Related]
15. Histological support for the difference between malignant hyperthermia susceptible (MHS), equivocal (MHE) and negative (MHN) muscle biopsies.
Mezin P; Payen JF; Bosson JL; Brambilla E; Stieglitz P
Br J Anaesth; 1997 Sep; 79(3):327-31. PubMed ID: 9389850
[TBL] [Abstract][Full Text] [Related]
16. Use of the calcium agonist BAY K 8644 for in vitro diagnosis of susceptibility to malignant hyperthermia.
Adnet PJ; Krivosic-Horber RM; Haudecoeur G; Adamantidis MM; Reyford GH; Imbenotte M; Cordonnier C
Br J Anaesth; 1990 Dec; 65(6):791-5. PubMed ID: 1702303
[TBL] [Abstract][Full Text] [Related]
17. Static v. dynamic tests in the in vitro diagnosis of malignant hyperthermia susceptibility.
Ranklev E; Fletcher R; Blomquist S
Br J Anaesth; 1986 Jun; 58(6):646-8. PubMed ID: 3707802
[TBL] [Abstract][Full Text] [Related]
18. Inositol 1,4,5-trisphosphate synthesis in mononuclear white blood cells of malignant hyperthermia-susceptible and normal human beings, following in vitro exposure to halothane, caffeine and ryanodine.
Martens U; Krause T; Scholz J; Wappler F; Steinrücke K; am Esch JS
Eur J Anaesthesiol; 2000 Jun; 17(6):364-72. PubMed ID: 10928436
[TBL] [Abstract][Full Text] [Related]
19. Influence of propranolol on the in vitro response to caffeine and halothane in malignant hyperthermia-susceptible muscle.
Ording H
Acta Anaesthesiol Scand; 1989 Jul; 33(5):405-8. PubMed ID: 2800978
[TBL] [Abstract][Full Text] [Related]
20. Multicentre evaluation of in vitro contracture testing with bolus administration of 4-chloro-m-cresol for diagnosis of malignant hyperthermia susceptibility.
Wappler F; Anetseder M; Baur CP; Censier K; Doetsch S; Felleiter P; Fiege M; Fricker R; Halsall PJ; Hartung E; Heffron JJ; Heytens L; Hopkins PM; Klingler W; Lehmann-Horn F; Nivoche Y; Tegazzin V; Tzanova I; Urwyler A; Weisshorn R; Schulte am Esch J
Eur J Anaesthesiol; 2003 Jul; 20(7):528-36. PubMed ID: 12884985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
